Lexeo Therapeutics, Inc. Common StockLXEONASDAQ
Loading
SG&A Expenses Over TimeExpanding
Percentile Rank100
3Y CAGR+57.7%
5Y CAGR+126.6%
Studio
Year-over-Year Change

Selling, general, and administrative expenses

3Y CAGR
+57.7%/yr
Annual compound
5Y CAGR
+126.6%/yr
Recent deceleration
Percentile
P100
Near historical high
vs 5Y Ago
59.7x
Strong expansion
Streak
5 yr
Consecutive growthExpanding
PeriodValueYoY Change
TTM$47.04M+48.5%
2024$31.68M+105.9%
2023$15.38M+28.2%
2022$12.00M+67.3%
2021$7.17M+810.9%
2020$787499.00-